【摘 要】
：
Aim:To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single, escalating subcutaneousinjections of an albumin-Exendin-4 conjugate in healthy rhesus monkeys.Methods:This stud
【机 构】
：
Key laboratory of drug metabolism, Academy of military medicine science.NO 27, taiping road, Haidian
【出 处】
：
第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu
论文部分内容阅读
Aim:To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single, escalating subcutaneousinjections of an albumin-Exendin-4 conjugate in healthy rhesus monkeys.Methods:This study investigated single, escalating subcutaneous dosesofE2HSA ranging from 0.3 to 2.7 mg; six healthy rhesus monkeys were randomized to each dose group.Parameters of safety, includingadverse events, were assessed.The pharmacokinetic profile was assessed over 12 days.Pharmacodynamic parameters (glucose and insulinconcentrations) were measured following a step-glucose infusion (day 2) and as part of an oral glucose tolerance test (OGTT) (day 3).Results:E2HSA was generally well tolerated with some increase in gastrointestinal symptoms with escalating doses.There were dosedependent decreases in food intake.The half-life of E2HSA was approximately 53 h, with Cmax occurring between 10 and 12 h in most monkeys.Evidence of increase in glucose-dependent insulin secretion and suppressionof serum glucose excursions were observed during an OGTT at all doses compared to placebo; no episodes of hypoglycaemia occurred.Conclusions:E2HSA showed an acceptable safety profile and exhibited the expected glucagon-like peptide-1 pharmacological effects onsatiety, glucosesuppression and insulin secretion with a long acting function.
其他文献
Purpose:To investigate the pharmacological effects of differenterlotinib (ER) and gemcitabine (GM) combination schedules byin vitro and in vivo experiments and PK/PD models in non-smallcell lung cance
Pediatric drug research is currently one of the new frontiers for clinical pharmacology.With the necessity of pediatric drug research and the special ethical considerations in pediatric clinical trial
INTRODUCTION Drug discovery for central nervous system (CNS) disorders has been challenged with markedly high attrition rate.This has driven extensive preclinical and clinical CNS pharmacokinetic (PK)
Background: Exposure-response model has been established in patients with psoriasis for Ustekinumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody that binds with high affinity to human
AIM: To develop a population pharmacokinetic model of adefovir dipivoxil in healthy volunteers and evaluate the effect of individual factors on the pharmacokinetics of adefovir dipivoxil.METHODS: Plas
The objective of this study was to assess ethnic difference of mycophenolic acid (MPA) and 7-Omycophenolic acid glucuronide (MPAG) pharmacokinetics (PK) among Chinese and Caucasian healthy subjects by
Background and Rationale: Physiologically-based pharmacokinetics (PBPK) modelling is a key component of model-based drug development and is increasingly embraced within the industry and regulatory aut
Biopharmaceutical industry has focused on cancer drug research and development in the past decades, however the success rate for oncology products is relatively low compared to other therapeutic areas
Purpose:Diabetic macular edema (DME) is a trequent manifestation of diabetic retinopathy which is the most common microvascular complications of diabetes mellitus, accounting for 13％ visual impairment
Objective:CPRC-Y is a pegylatedrecombinant human growth hormone (rhGH) developed with the aim of reducing serum clearance and thereby prolonging the exposure leading to once-weekly sc administration.T